The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kryukov A.I.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology;
Pirogov Russian National Research Medical University

Gurov A.V.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology;
Pirogov Russian National Research Medical University

Fomina D.S.

City Clinical Hospital No. 52;
Sechenov First Moscow State Medical University (Sechenov University)

Tovmasyan A.S.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Rabadanov G.K.

L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Zhogoleva T.N.

Pirogov Russian National Research Medical University

Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review

Authors:

Kryukov A.I., Gurov A.V., Fomina D.S., Tovmasyan A.S., Rabadanov G.K., Zhogoleva T.N.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2025;90(4): 96‑104

DOI: 10.17116/otorino20259004196

Read: 504 times

Buy for 300₽
Contact the author
Table of contents

MONOCLONAL ANTIBODIES IN THE TREATMENT OF RECURRENT POLYPOSIS RHINOSINUSITIS. LITERATURE REVIEW
MONOCLONAL ANTIBODIES IN THE TREATMENT OF RECURRENT POLYPOSIS RHINOSINUSITIS. LITERATURE REVIEW

To cite this article:

Kryukov AI, Gurov AV, Fomina DS, Tovmasyan AS, Rabadanov GK, Zhogoleva TN. Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review. Russian Bulletin of Otorhinolaryngology. 2025;90(4):96‑104. (In Russ.)
https://doi.org/10.17116/otorino20259004196

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Anti­fungal immu­nity in patients with chro­nic rhinosinusitis with nasal polyps. Russian Bulletin of Otorhinolaryngology. 2024;(6):40-45
A case of prolonged remi­ssion after discontinuation of biological therapy in a patient with severe unco­ntrolled chro­nic rhinosinusitis with nasal polyps. Russian Bulletin of Otorhinolaryngology. 2024;(6):99-106
Immu­notherapy in the treatment of chro­nic poly­pous rhinosinusitis with como­rbid bronchial asthma. Russian Bulletin of Otorhinolaryngology. 2025;(1):29-34
Esophageal pathology and bronchial asthma: pathogenetic inte­ractions and possibilities for therapy opti­mization. Russian Journal of Preventive Medi­cine. 2024;(11):129-134
Chro­nic inflammation in case of obesity-associated diseases. Russian Journal of Preventive Medi­cine. 2025;(1):115-121
Acce­ssibility of health and preventive care for patients with bronchial asthma. Journal of Respiratory Medi­cine. 2025;(1):15-22
Effi­cacy of dupi­lumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):204-209
Neutrophil elastase as a promising biomarker of low-grade inflammation in chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(4):142-148
Syne­rgistic effi­ciency of preformed physical factors and dupi­lumab in the treatment of poly­pous rhinosinusitis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):16-23
Rela­tionship between oxidative stress patterns and proinflammatory cyto­kines in patients with poly­pous rhinosinusitis under the course of therapeutic physical factors. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):42-49
Abstract:

This article is devoted to the problem of the effectiveness of therapy of recurrent polyposis rhinosinusitis and the choice of the most effective drug from the group of monoclonal antibodies. The wide prevalence of the disease, as well as the low level of effectiveness of existing treatment methods, such as glucocorticosteroid (topical and topical) therapy, antibacterial therapy and available surgical methods of treatment (polypotomy, endoscopic polysinusitomy) allow us to conclude that the existing methods of treatment for recurrent polyposis process do not allow to achieve a stable positive result. Various undesirable phenomena with prolonged use of steroidal drugs, as well as the need for repeated rhinosinusosurgery in case of recurrence of this process, make doctors-otorhinolaryngologists around the world to look for new treatment options for polyposis rhinosinusitis, one of these methods is the use of monoclonal antibodies. Currently, the treatment of recurrent polyposis rhinosinusitis is the most urgent task at the junction of two specialties: otorhinolaryngology and allergology-immunology. Polyposis rhinosinusitis has different courses. The phenotype most prone to recurrent growth of nasal polyps and the formation of concomitant bronchial asthma is induced by Th-2 immune response. In this case, the above-mentioned methods of treatment do not always help to achieve a stable remission. Monoclonal antibodies can be an additional method of treatment in this situation, which targetingly block certain parts of the Th2-inflammatory reaction, thereby controlling the symptoms. However, the increasing number of available monoclonal antibody preparations creates a problem of choosing the most optimal one. Due to the fact that biological therapy offers great therapeutic opportunities in modern clinical practice, further study and development of this direction in otorhinolaryngology is necessary.

Keywords:

polyposis rhinosinusitis
bronchial asthma
monoclonal antibodies
biological therapy

Authors:

Kryukov A.I.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology;
Pirogov Russian National Research Medical University

Gurov A.V.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology;
Pirogov Russian National Research Medical University

Fomina D.S.

City Clinical Hospital No. 52;
Sechenov First Moscow State Medical University (Sechenov University)

Tovmasyan A.S.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Rabadanov G.K.

L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Zhogoleva T.N.

Pirogov Russian National Research Medical University

Received:

02.12.2024

Accepted:

07.04.2025

Close metadata

References:

  1. Tojima I, Kouzaki H, Shimizu S, Ogawa T, Arikata M, Kita H, Shimizu T. Group 2 innate lymphoid cells are increased in nasal polyps in patients with eosinophilic chronic rhinosinusitis. Clinical Immunology. 2016;170:1-8.  https://doi.org/10.1016/j.clim.2016.07.010
  2. Han JK. Subclassification of chronic rhinosinusitis. The Laryngoscope. 2013;123:S15-S27.  https://doi.org/10.1002/lary.23979
  3. Nosulya EV. The prevalence of polypous rhinosinusitis among the urban population of Eastern Siberia. Russian Rhinology. 2007;1:4-8. (In Russ.).
  4. Piskunov GZ. Clinical phenotypes of polypous rhinosinusitis. Russian Rhinology. (In Russ.). https://doi.org/10.17116/rosrino201927041224
  5. Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. American Journal of Respiratory and Critical Care Medicine. 2022;205(1):17-35.  https://doi.org/10.1164/rccm.202109-2205PP
  6. Samoliński B, Szczesnowicz-Dabrowska P. Relationship between inflammation of upper and lower respiratory airways. The Polish Otolaryngology. 2002;56(1):49-55. 
  7. Serrano E, Neukirch F, Pribil C, Jankowski R, Klossek JM, Chanal I, El Hasnaoui A. Nasal polyposis in France: Impact on sleep and quality of life. The Journal of Laryngology and Otology. 2005;119(7):543-549.  https://doi.org/10.1258/0022215054352108
  8. Xiao J, Wu WX, Ye YY, Lin WJ, Wang L. A network meta-analysis of randomized controlled trials focusing on different allergic rhinitis medications. American Journal of Therapeutics. 2016;23(6):e1568-e1578. https://doi.org/10.1097/mjt.0000000000000242
  9. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Meco C, Matricardi PM, O’Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kawauchi H, Kjeldsen A, Klimek L, Krzeski A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdjoubi A, Mesbahi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Orlandi R, Otori N, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raftopulos M, Rombaux P, Riechelmann H, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Sindvongs K, Soklic Kosak T, Stjarne P, Sutikno B, Steinsvag S, Tantilipikorn P, Thanaviratananich S, Tran T, Urbancic J, Valiulius A, Vasquez de Aparicio C, Vicheva D, Virkkula PM, Vicente G, Voegels R, Wagenmann MM, Wardani RS, Welge-Lussen A, Witterick I, Wright E, Zabolotniy D, Zsolt B, Zwetsloot CP. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.  https://doi.org/10.4193/rhin20.600
  10. Piskunov GZ. Nasal polyposis, paranasal sinuses and its treatment. Russian Rhinology. 2003;2:10-13. (In Russ.).
  11. Lund VJ, Kennedy DW. Quantification for staging sinusitis. Annals of Otology, Rhinology and Laryngology.1995;104(10 Suppl):17-21. 
  12. Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Annals of Allergy, Asthma and Immunology. 2018;120(5):504-511.e4.  https://doi.org/10.1016/j.anai.2018.01.030
  13. Moiseeva YuP, Piskunov GZ. Biological therapy — new possibilities for the treatment of T2-induced chronic rhinosinysitis with nasal polyps. Farmakologiya i farmakoterapiya. 2022;S1:44-47. (In Russ.). https://doi.org/10.46393/27132129_2022_S_44
  14. Kuzubova NA, Titova ON. T2-associated diseases: focus on the comorbid patient. Meditsinskij sovet. 2020;17:57-64. (In Russ.).
  15. Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. Journal of Clinical Medicine. 2019;8(9):1375. https://doi.org/10.3390/jcm8091375
  16. Van Bruaene N, Pérez-Novo CA, Basinski TM, Van Zele T, Holtappels G, De Ruyck N, Schmidt-Weber C, Akdis C, Van Cauwenberge P, Bachert C, Gevaert P. T-cell regulation in chronic paranasal sinus disease. Journal of Allergy and Clinical Immunology. 2008;121(6):1435-1441.e3.  https://doi.org/10.1016/j.jaci.2008.02.018
  17. Khramova RN, Eliseeva TI, Potemkina TE. Epithelial barrier dysfunction in bronchial asthma. Vestnik meditsinskogo instituta «Reaviz»: reabilitatsiya, vrach i zdorov’e. 2022;4(58):56-61. (In Russ.). https://doi.org/10.20340/vmi-rvz.2022.4.MORPH.3
  18. Peredelskaya MYu, Sebyakina OV, Nenasheva NM, Peredelsky YuA. An approach to the treatment of a patient with T2-associated asthma using biological therapy: a clinical case from real practice. Farmateka. 2021;28(5):127-130. (In Russ.). https://doi.org/10.18565/pharmateca.2021.5.127-135
  19. Wenzel S. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Medicine. 2012;18:716-725.  https://doi.org/10.1038/nm.2678
  20. Savlevich EL, Cherenkova VA, Molodnitskaya AY. Principles of basic therapy of polypous rhinosinusitis. Meditsinskij sovet. 2020;(16):73-78.  https://doi.org/10.21518/2079-701X-2020-16-73-78
  21. Ryazantsev SV. Tactics of treatment of polypous rhinosinusitis. Rossijskaya otorinolaringologiya. 2017;2(87):162-169. (In Russ.). https://doi.org/10.18692/1810-4800-2017-2-162-169
  22. Budkovaia MA, Ryazantsev SV. Comprehensive assessment of the effectiveness and safety of conservative treatment of chronic rhinosinusitis. Russian Rhinology. 2020;28(3):125-131. (In Russ.). https://doi.org/10.17116/rosrino202028031125
  23. Bachert C, Marple B, Hosemann W, Cavaliere C, Wen W, Zhang N. Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(5):1514-1519. https://doi.org/10.1016/j.jaip.2020.03.007
  24. Moiseeva YuP, Piskunov GZ. The development of a personalized approach in the treatment of chronic rhinosinusitis with nasal polyps. Russian Bulletin of Otorhinolaryngology. 2022;87(3):40-45. (In Russ.). https://doi.org/10.17116/otorino20228703140
  25. Krasilnikova SV, Ovsyannikov DYu, Eliseeva TI, Tush EV, Bolshova EV, Larin RA, Frolov PA, Balabolkin II. Thymic stromal lymphopoietin as a predictor of hypertrophic changes in the nasal mucosa in children with atopic bronchial asthma and allergic rhinitis. Pediatriya. Zhurnal im. G.N. Speranskogo. 2020;99(4):71-77.  https://doi.org/10.24110/0031-403X-2020-99-4-71-78
  26. Boiko NV, Lodochkina OE, Kit MM, Kuleshova VG, Nedashkovskaya NG. Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma. Russian Bulletin of Otorhinolaryngology. 2021;86(2):43-48. (In Russ.). https://doi.org/10.17116/otorino20218602143
  27. Savlevich EL, Egorov VI, Shachnev KN, Tatarenko NG. The analysis of polypous rhinosinusitis treatment regimens in the Russian Federation. Rossiiskaya otorinolaringologiya. 2019;18(1):124-134. (In Russ.). https://doi.org/10.18692/1810-4800-2019-1-124-134
  28. Piskunov GZ. Physiological and pathophysiological basis for functional endoscopic sinus surgery. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018;24(1):23-28. (In Russ.).
  29. Kurbacheva OM, Dyneva ME, IlinaN.I. Dupilumab: basic aspects and applications to T2-mediated diseases. Meditsinskij sovet. 2021;(16):186-196. (In Russ.). https://doi.org/10.21518/2079-701X-2021-16-186-196
  30. Kosyakov SYa, Pchelenok EV. Surgical treatment of chronic rhinosinusitis. Analytical review. Russian Rhinology. 2013;21(4):30-33. (In Russ.).
  31. Lopatin AS. Modern theories of the pathogenesis of polypous rhinosinusitis. Pul’monologiya. 2003;5:110-115. (In Russ.).
  32. Allakhveranov DAO, Yunusov AS, Ryabinin AG. Long-term results of endoscopic methods of treatment of chronic polypous rhinosinusitis. Rossijskaya otorinolaringologiya. 2015;3(76):158-160. (In Russ.).
  33. Shirokaya AV, Svistushkin VM, Shatokhina SN, Shabalin VN. Evaluation of the efficiency of treatment of patients with polypous rhinosinusitis and forecast for disease course. Rossijskaya otorinolaringologiya. 2013;2(63):96-104. (In Russ.).
  34. Hopkins C. Ethical dilemmas associated with the introduction of biologic treatments in chronic rhinosinusitis with nasal polyps. Rhinology. 2022;60(3):162-168.  https://doi.org/10.4193/Rhin21.477
  35. Ryazantsev SV. Modern views on the treatment of polypous rhinosinusitis. Prakticheskaya pul’monologiya. 2007;4(22-26). (In Russ.).
  36. Ryazantsev SV, Maryanovsky AA. Polipoznye rinosinusity: etiologiya, patogenez, klinika i sovremennye metody lecheniya. SPb: Politekhnika; 2006:16-20. (In Russ.).
  37. Ryazantsev SV, Artyushkina VK, Nacharov PV, Lapteva MA. Modern aspects of systemic corticosteroid therapy in patients with chronic rhinosinusitis with nasal polyps. Rossijskaya otorinolaringologiya. 2013;2(63):114-121. (In Russ.).
  38. Budkovaya MA. Use of systemic corticosteroid therapy in patients with firstly revealed the nasal polyps. Rossijskaya otorinolaringologiya. 2014;1(68):15-23. (In Russ.).
  39. Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, Mullol J, Gevaert P, Klimek L, Prokopakis E, Knill A, Cavaliere C, Hopkins C, Hellings P. eEUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. Journal of Allergy and Clinical Immunology. 2021;147(1):29-36.  https://doi.org/10.1016/j.jaci.2020.11.013
  40. Zhou J, Yuan F, Huang T, Zhu L, Wu D. Current understanding of disease control and its application in patients with chronic rhinosinusitis. Frontiers in Cellular and Infection Microbiology. 2023; 13:1104444. https://doi.org/10.3389/fcimb.2023.1104444
  41. Kapucu B, Cekin E, Erkul BE, Cincik H, Gungor A, Berber U. The effects of systemic, topical, and intralesional steroid treatments on apoptosis level of nasal polyps. Otolaryngology — Head and Neck Surgery. 2012;147(3):563-567.  https://doi.org/10.1177/0194599812446678
  42. Bonfils P. Evaluation of the combined medical and surgical treatment in nasal polyposis. I: functional results. Acta Otolaryngologica. 2007;127(4):436-446.  https://doi.org/10.1080/00016480600895078
  43. Lopatin AS. Medical treatment of polypous rhinosinusitis. Consilium Medicum. 2002;4(9):461-468. (In Russ.).
  44. Savlevich EL, Esakova NV, Egorov VI. Polypous rhinosinusitis: possibilities of anti-inflammator therapy. Rossijskaya otorinolaringologiya. 2023;22(5):100-110. (In Russ.). https://doi.org/10.18692/1810-4800-2023-5-100-110
  45. Savvateeva DM, Lopatin AS, Kochetkov PA. Olfactory function in patients with polypous rhinosinusitis before and after drug and surgical treatment. Russian Rhinology. 2011;19(2):25-25. (In Russ.).
  46. Campbell RG. Risks and management of long-term corticosteroid use in chronic rhinosinusitis. Current Opinion in Otolaryngology and Head and Neck Surgery. 2018;26(1):1-7.  https://doi.org/10.1097/MOO.0000000000000421
  47. Snidvongs K, Kalish L, Sacks R, Craig JC, Harvey RJ. Topical steroid for chronic rhinosinusitis without polyps. Cochrane Database of Systematic Reviews. 1996;2011(8):CD009274. https://doi.org/10.1002/14651858.CD009274
  48. Zhang YY, Lou HF, Wang CS, Zhang L. [Mechanisms underlying glucocorticoid resistance in chronic rhinosinusitis with nasal polyps]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery. 2018;53(2):154-160.  https://doi.org/10.3760/cma.j.issn.1673-0860.2018.02.017
  49. Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, Canonica GW, Deneyer L, Desrosiers M, Diamant Z, Han J, Heffler E, Hopkins C, Jankowski R, Joos G, Knill A, Lee J, Lee SE, Mariën G, Pugin B, Senior B, Seys SF, Hellings PW. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312-2319. https://doi.org/10.1111/all.13875
  50. Dennis SK, Lam K, Luong A. A review of classification schemes for chronic rhinosinusitis with nasal polyposis endotypes. Laryngoscope Investigative Otolaryngology. 2016;1(5):130-134.  https://doi.org/10.1002/lio2.32
  51. Budkovaya MA, Ryazantsev SV, Dvoryanchikov VV, Rebrova SA, Maltseva GS. Prospects for the Use of Biological Therapy in Chronic Rhinosinusitis with Nasal Polyps and Other T2-Associated Immuno-Mediated Inflammatory Diseases. Effektivnaya farmakoterapiya. 2021;17(18):16-20.  https://doi.org/10.33978/2307-3586-2021-17-18-16-20
  52. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332(6162):323-327.  https://doi.org/10.1038/332323a0
  53. Al-Ahmad M, Alsaleh S, Al-Reefy H, Al Abduwani J, Nasr I, Al Abri R, Alamadi AMH, Fraihat AA, Alterki A, Abuzakouk M, Marglani O, Rand HA. Expert opinion on biological treatment of chronic rhinosinusitis with nasal polyps in the gulf region. Journal of Asthma and Allergy. 2022;15:1-12.  https://doi.org/10.2147/JAA.S321017
  54. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. The Lancet. 2019;394(10209):1638-1650. https://doi.org/10.1016/S0140-6736(19)31881-1
  55. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. Journal of Allergy and Clinical Immunology. 2020;146(3):595-605.  https://doi.org/10.1016/j.jaci.2020.05.032
  56. Fokkens WJ, Mullol J, Kennedy D, Philpott C, Seccia V, Kern RC, Coste A, Sousa AR, Howarth PH, Benson VS, Mayer B, Yancey SW, Chan R, Gane SB. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In‐depth sinus surgery analysis. Allergy. 2023;78(3):812-821.  https://doi.org/10.1111/all.15434
  57. Yilmaz I, Türk M, Nazik Bahçecioğlu S, Tutar N, Gülmez I. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilicasthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study. Turkish Journal of Medical Sciences. 2020;50(2):433-441.  https://doi.org/10.3906/sag-1912-62
  58. Borish L, Cohen NA, Chupp G, Hopkins C, Wagenmann M, Sousa AR, Smith SG, Silver J, Yang S, Mayer B, Yancey SW, Chan RH, Fokkens W. Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps. Annals of Allergy, Asthma and Immunology. 2022;129(2):160-168.  https://doi.org/10.1016/j.anai.2022.04.004
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.